Similar articles

• The tamoxifen trial - a double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer.

  Stewart HJ, Forrest AP, Gunn JM, Hamilton T, Langlands AO, McFadyen IJ, Roberts MM. Stewart HJ, et al. Eur J Cancer (1965). 1980;Suppl 1:83-8. Eur J Cancer (1965). 1980. PMID: 7032945 Clinical Trial. No abstract available.
• Effect of prednisolone on hormone profiles during primary endocrine treatment of advanced breast cancer.

  Blackburn AM, Wang DY, Bulbrook RD, Thomas BS, Kwa HG, Hoare SA, Rubens RD. Blackburn AM, et al. Cancer Treat Rep. 1984 Dec;68(12):1447-53. Cancer Treat Rep. 1984. PMID: 6239689 Clinical Trial.
• Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).

  Beattie MS, Costantino JP, Cummings SR, Wickerham DL, Vogel VG, Dowsett M, Folkerd EJ, Willett WC, Wolmark N, Hankinson SE. Beattie MS, et al. J Natl Cancer Inst. 2006 Jan 18;98(2):110-5. doi: 10.1093/jnci/djj011. J Natl Cancer Inst. 2006. PMID: 16418513
• The Wisconsin Tamoxifen Study: toxicity in node-negative postmenopausal women.

  Love RR. Love RR. Cancer Invest. 1988;6(5):601-5. doi: 10.3109/07357908809082126. Cancer Invest. 1988. PMID: 3063340 Review. No abstract available.
• Hormonal control of breast cancer growth in women and rats.

  Pearson OH, Manni A. Pearson OH, et al. Curr Top Exp Endocrinol. 1978;3:75-92. doi: 10.1016/b978-0-12-153203-1.50009-2. Curr Top Exp Endocrinol. 1978. PMID: 350503 Review. No abstract available.